Navigation Links
Children's national co-leads nationwide study of landmark sickle cell treatment
Date:8/18/2008

WASHINGTON, DCChildren's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease. Children's National will join more than 20 other medical institutions in the first-ever Phase II clinical trial of this treatment. If successful, the Sickle Cell Unrelated Transplant (SCURT) trial has the potential to extend a promising and possibly curative treatment option to more severely affected patients. Sickle cell disease affects approximately 70,000 people in the United States.

For many years, doctors have used blood or marrow transplants to treat severe cases of sickle cell disease. However these treatments have been available only to patients with a matched family member to donate blood or marrow stem cells. Only 14 percent of severe sickle cell cases have a matched donor within their family. Successful transplants using unrelated donors could create a viable treatment option for more sickle cell patients.

"Blood and marrow transplantation from unrelated donors has been routinely utilized to treat treatment-refractory leukemia and lymphoma for almost two decades," said Dr. Kamani, co-principal investigator of the study. "Preliminary results from the few unrelated donor transplants that have been performed for other non-malignant conditions show great promise for those who suffer a severely diminished quality of life due to sickle cell disease. Participants in this large-scale study will help us understand how to better treat, and possibly even cure, sickle cell disease for more people."

Starting in late August, the clinical trial will enroll 45 patients ages 3 to 16 with severe symptoms of sickle cell disease, including stroke, recurring acute chest syndrome, or frequent pain crises. For all marrow and cord blood transplants, patients must undergo intense chemotherapy to prevent their immune systems from rejecting donor cells. This study will use a reduced-intensity chemotherapy to minimize side effects and increase the likelihood that the donor cells will be accepted by the body. After the transplant, participants will be followed for two years to gauge the effectiveness of the transplant at minimizing the ravages of sickle cell disease.


'/>"/>

Contact: Emily Dammeyer
edammeye@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related biology news :

1. Story tips from the US Department of Energys Oak Ridge National Laboratory, August 2008
2. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
3. NYU Langone Medical Centers tip sheet to the International Conference on Alzheimers Disease 2008
4. New study spotlights National Institutes of Health grant outcomes for clinical research
5. International conference to release new findings on smell and taste
6. National Institutes of Health award Williams professor $217,710 research grant
7. Story tips from the Department of Energys Oak Ridge National Laboratory, July 2008
8. International team identifies 21 new genetic risk factors for Crohns disease
9. 2008 ASABE Annual International Meeting
10. PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative
11. Oak Ridge pegged for national ecological network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... YORK , Feb. 7, 2017 ... Driven largely by the confluence of organizations, desires ... distaste for knowledge-based systems (password and challenge questions), ... industrial, and government systems. The market is driven ... a demarcation between consumer and enterprise uses cases, ...
(Date:2/7/2017)... BEACH, New York , February 7, 2017 /PRNewswire/ ... known as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" ... identity management and electronic transaction processing services, is pleased ... reorganization of the Company. Effective January 31, ... of the Board of Directors, CEO and President.  An ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... business in Hong Kong. , Nerium International is proud to introduce its Age-Defying ... Contour Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 /PRNewswire/ ... research report "Biomarkers Market by Product (Consumables, Service), ... Disorders), Application (Diagnostics Development, Drug Discovery and Development, ... MarketsandMarkets, the market is projected to reach USD ... in 2016, growing at a CAGR of 13.8% ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology: